Last reviewed · How we verify
Lysipressin (LYPRESSIN)
LYPRESSIN, marketed by Novartis, is a lysipressin-based treatment for partial central diabetes insipidus, competing in a niche but critical therapeutic area. Its key strength lies in its mechanism of action, which effectively mimics the antidiuretic hormone to regulate fluid balance, offering a targeted solution for patients. The primary risk is the upcoming patent expiry in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | LYPRESSIN |
|---|---|
| Sponsor | Novartis |
| Drug class | lypressin |
| Target | Vasopressin receptor |
| Modality | Recombinant protein |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
- Partial Central Diabetes Insipidus
Common side effects
Key clinical trials
- Comparison of Terlipressin Versus Octreotide in Patients With Hepatorenal Syndrome (NA)
- Effects of Terlipressin and Somatostatin on Portal Pressure in Patients Undergoing Living Donor Liver Transplantation (NA)
- Terlipressin in Combined Hepatorenal Syndrome in Patients With Signs of Chronic Renal Disease
- Terlipressin vs. Somatostatin in Cirrhotic Patients With Acute Gastrointestinal Bleeding and Acute Kidney Injury (NA)
- Effect of Terlipressin for Intraoperative Blood Pressure Management in Kidney Transplantation (NA)
- Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome (PHASE2)
- HRS-AKI Treatment With TIPS in Patients With Cirrhosis (NA)
- Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lysipressin CI brief — competitive landscape report
- Lysipressin updates RSS · CI watch RSS
- Novartis portfolio CI